Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Adverse reactions related to brentuximab vedotin use: A real-life retrospective study

Abstract : Post-marketing data regarding brentuximab vedotin (BV) are sparse. The aim of this study was to assess the frequency and nature of significant adverse drug reactions (ADRs) in patients treated with BV in a real-world setting. We conducted a systematic retrospective study of patients treated with BV in a French university hospital. Significant ADRs were collected using the electronic patient records. Between January 2009 and December 2016, 39 patients received BV. Median age was 43.2 and 53.8% were males. Overall, 20 patients (51.3%) experienced at least one significant ADR and 24 reactions were reported in total. Twelve (50%) out of 24 ADRs were severe. The most frequently observed significant ADRs were peripheral sensory neuropathy and CMV reactivation. ADRs led to drug discontinuation for 4 patients and dose reduction for 6 patients. Only 29.2% of the events were spontaneously reported. Prospective monitoring is needed to better assess BV safety.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02555942
Contributeur : Amandine Michel-Avella <>
Soumis le : lundi 27 avril 2020 - 16:55:01
Dernière modification le : vendredi 15 mai 2020 - 12:22:09

Identifiants

Collections

Citation

B. Clarivet, L. Vincent, L. Vergely, V. Bres, K. Foglia, et al.. Adverse reactions related to brentuximab vedotin use: A real-life retrospective study. Thérapie, EDP Sciences, 2019, 74 (3), pp.343-346. ⟨10.1016/j.therap.2018.07.004⟩. ⟨hal-02555942⟩

Partager

Métriques

Consultations de la notice

25